MARKET

BCYC

BCYC

Bicycle Therapeutics Limited
NASDAQ
27.44
-1.01
-3.55%
After Hours: 27.44 0 0.00% 16:00 02/03 EST
OPEN
28.40
PREV CLOSE
28.45
HIGH
28.42
LOW
26.96
VOLUME
365.22K
TURNOVER
0
52 WEEK HIGH
51.93
52 WEEK LOW
12.08
MARKET CAP
814.68M
P/E (TTM)
-8.0441
1D
5D
1M
3M
1Y
5Y
EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target
EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target
MT Newswires · 01/05 08:04
Bicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapy
Seeking Alpha · 01/04 12:52
BRIEF-Bicycle Therapeutics Announces FDA Fast Track Designation For Bt8009
Reuters · 01/04 12:43
Bicycle Therapeutics Receives Fast Track Designation From FDA for Urothelial Cancer Treatment
Bicycle Therapeutics Receives Fast Track Designation From FDA for Urothelial Cancer Treatment
MT Newswires · 01/04 08:55
JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $46
Benzinga · 11/09/2022 13:14
Bicycle Therapeutics Third Quarter 2022 Earnings: Misses Expectations
Bicycle Therapeutics ( NASDAQ:BCYC ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.04m (down 30% from...
Simply Wall St. · 11/09/2022 13:03
--JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating
--JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating
MT Newswires · 11/09/2022 10:33
Bicycle Therapeutics Announces First Patient Dosed In BT8009 Phase II Expansion Cohorts And Provides Program Update
Benzinga · 11/08/2022 12:05
More
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist. The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Webull offers kinds of Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ:BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.